Singapore - English - HSA (Health Sciences Authority)

aerobe pte. ltd. - general & plastic surgery - the medilux is clinically intended for the treatment of the following skin conditions: • treatment of acne vulgaris • wound repair • relief from wound pain, inflammation and swelling (results may vary)

Australia - English - Department of Health (Therapeutic Goods Administration)

aerobe pty ltd - 36313 - continuous passive motion joint exerciser - lower limb rehabilitation robot - rehabilitation exercise device intended for medical purposes of rehabilitation and physiotherapy, including therapy and evaluation of patient?s state

Australia - English - Department of Health (Therapeutic Goods Administration)

aerobe pty ltd - 63314 - electronic torsional hand exerciser - rehabilitation exercise device intended for medical purposes of rehabilitation and physiotherapy, including therapy and evaluation of patient?s state.

Australia - English - Department of Health (Therapeutic Goods Administration)

aerobe pty ltd - 47541 - bioelectrical signal processing application software - persyst eeg review and analysis software is intended for the review, monitoring and analysis of eeg recordings made by electroencephalogram (eeg) devices using scalp electrodes and to aid neurologists in the assessment of eeg. this device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.

Canada - English - Health Canada

zep manufacturing company of canada - o-phenylphenol; p-tert-pentylphenol; alcohol anhydrous - aerosol - 0.18%; 0.045%; 49.95% - o-phenylphenol 0.18%; p-tert-pentylphenol 0.045%; alcohol anhydrous 49.95% - disinfectants (for agents used on object)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 500 mg - suppository - excipient ingredients: hard fat - anaerobic infections: suppositories treatment of anaerobic infection in patients for whom oral medication is not possible or is contraindicated. prevention of anaerobic infection in high risk situations in patients for whom oral medication is not possible or is contraindicated. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia. note. metronidazole is inactive against aerobic and facultative anaerobic bacteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; lactose monohydrate; magnesium stearate; disodium edetate; sodium starch glycollate; guar gum; colloidal anhydrous silica; ethylcellulose - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate; ethylcellulose; colloidal anhydrous silica; guar gum; magnesium stearate; disodium edetate - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - clindamycin hydrochloride, quantity: 162.868 mg - capsule, hard - excipient ingredients: lactose; purified talc; microcrystalline cellulose; povidone; magnesium stearate; sodium starch glycollate; titanium dioxide; brilliant blue fcf; purified water; gelatin; sodium lauryl sulfate; tartrazine; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - clindamycin lu (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin lu capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.,anaerobes:,serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and skin structure infections, septicaemia,staphylococci: serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis,pneumococci: serious respiratory tract infections,adjunctive therapy: in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy.,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.